Patterns of Recurrence of Cutaneous Melanoma: A Literature Review

Patterns of Recurrence of Cutaneous Melanoma: A Literature Review

Authors

  • Dominga Peirano Department of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Francisca Donoso Department of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Sebastian Vargas Department of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Leonel Hidalgo Department of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Rosario Agüero Department of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Pablo Uribe Department of Dermatology, Escuela de Medicina; Melanoma and Skin Cancer Unit, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Sebastian Mondaca Melanoma and Skin Cancer Unit, Escuela de Medicina; Department of Medical Oncology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Cristian Patricio Navarrete-Dechent Department of Dermatology, Facultad de Medicina; Melanoma and Skin Cancer Unit, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile https://orcid.org/0000-0003-4040-3640

Keywords:

melanoma, staging, recurrence, metastasis, skin cancer, imaging, screening

Abstract

The incidence of melanoma has been dramatically increasing over the last decades. Melanoma is considered to have a high metastatic potential and it can progress due to hematogenous metastasis or via lymphatic vessels. Different patterns of recurrence have been described, namely, local, satellite, and in transit metastasis (LCIT), lymphatic, and systemic metastasis. With a more advanced melanoma stage at diagnosis, there is a higher risk for systemic metastasis in comparison to LCIT; in contrast, early-stage melanoma tends to recur more frequently as LCIT and less commonly as systematic metastasis. The aim of this review was to summarize the patterns of recurrence of cutaneous melanoma, giving the clinician a practical summary for diagnosis, prognosis, and surveillance. There is a knowledge gap of the common patterns of recurrence that needs to be addressed to better identify patients at high risk of disease recurrence and personalize surveillance strategies as well as patient counseling.

References

Berger AC, Ollila DW, Christopher A, et al. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma. J Am Coll Surg. 2017;224(4):652-9. DOI: 10.1016/j.jamcollsurg.2016.12.038. PMID: 28189663.

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. DOI: 10.3322/caac.21763. PMID: 36633525.

O’Connell EP, O’Leary DP, Fogarty K, Khan ZJ, Redmond HP. Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy. Melanoma Res. 2016;26(1):66-70. DOI: 10.1097/CMR.0000000000000211. PMID: 26460498.

Surveillance, Epidemiology, and End Results (SEER) Program . Cancer Stat Facts: Melanoma of the Skin. Accessed February 7, 2023. https://seer.cancer.gov/statfacts/html/melan.html

Adler NR, Haydon A, McLean CA, Kelly JW, Mar VJ. Metastatic pathways in patients with cutaneous melanoma. Pigment Cell Melanoma Res. 2017;30(1):13-27. DOI: 10.1111/pcmr.12544. Epub 2016 Nov 30. PMID: 27900851.

Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147(1):62-70. DOI: 10.1046/j.1365-2133.2002.04867.x. PMID: 12100186.

Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86(4):172-8. DOI: 10.1002/jso.20079. PMID: 15221923.

Deschner B, Wayne JD. Follow-up of the melanoma patient. J Surg Oncol. 2019;119(2):262-8. DOI: 10.1002/jso.25324. PMID: 30548539.

Yee VSK, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. junio de 2005;12(6):429-39. DOI: 10.1245/ASO.2005.03.074. PMID: 15886905.

Cohn-Cedermark G, Månsson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol Stockh Swed. 1999;38(5):549-57. DOI: 10.1080/028418699431122. PMID: 10427942.

Cromwell KD, Ross MI, Xing Y, et al. Variability in melanoma post-treatment surveillance practices by country and physician specialty: A systematic review. Melanoma Res. 2012;22(5):376-85. DOI: 10.1097/CMR.0b013e328357d796. PMID: 22914178

Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022;170:256-84. DOI: 10.1016/j.ejca.2022.04.018. PMID: 35623961.

Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-50. DOI: 10.1016/j.jaad.2018.08.055. PMID: 30392755.

Cancer Council Australia Melanoma Guidelines. Clinical practice guidelines for the diagnosis and management of melanoma. Accessed February 7, 2023. https://wiki.cancer.org.au/australia/Guidelines:Melanoma

Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. Clin Epidemiol. 2016;8:109-22. DOI: 10.2147/CLEP.S99021. PMID: 27307765.

Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009;16(4):941-7. DOI: 10.1245/s10434-008-0238-y. PMID: 19101766.

Barbour S, Mark Smithers B, Allan C, et al. Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable? Ann Surg Oncol. 2015;22(12):4052-9. DOI: 10.1245/s10434-014-4356-4. PMID: 25582744.

Turner RM, Bell KJL, Morton RL, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol. 2011;29(35):4641-6. DOI: 10.1200/JCO.2010.34.2956. PMID: 22067399.

Damude S, Hoekstra-Weebers JEHM, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year. Ann Surg Oncol. 2016;23(9):2762-71. DOI: 10.1245/s10434-016-5263-7. PMID: 27194552.

Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042-7. DOI: 10.1200/JCO.2009.26.2063. PMID: 20479405.

Koskivuo I, Kemppainen J, Giordano S, al. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma. Acta Oncol Stockh Swed. 2016;55(11):1355-9. DOI: 10.1080/0284186X.2016.1213879. PMID: 27553064.

Bleicher J, Swords DS, Mali ME, et al. Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance. J Surg Oncol. 2020;122(8):1770-7. DOI:10.1002/jso.26214. PMID: 33098702.

Hayes AJ, Moskovic E, O’Meara K, et al. Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma. Br J Surg. 2019;106(6):729-34. DOI: 10.1002/bjs.11112. PMID: 30816996.

Lee AY, Droppelmann N, Panageas KS, et al. Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. Ann Surg Oncol. 2017;24(4):939-46. DOI: 10.1245/s10434-016-5642-0. PMID: 27804026.

Livingstone E, Eigentler TK, Windemuth-Kieselbach C, et al. Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study. Br J Dermatol. 2015;172(6):1646-50. DOI: 10.1111/bjd.13612. PMID: 25495472.

Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol. 1999;140(2):249-54. DOI: 10.1046/j.1365-2133.1999.02657.x. PMID: 10233217.

Sparks DS, Read T, Lonne M, et al. Primary cutaneous melanoma of the scalp: Patterns of recurrence. J Surg Oncol. 2017;115(4):449-54. DOI: 10.1002/jso.24535. PMID: 28035664.

Oh Y, Choi S, Cho MY, et al. Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations. J Am Acad Dermatol. 2020;83(4):1071-9. DOI: 10.1016/j.jaad.2019.09.029. PMID: 31562946.

Leeneman B, Franken MG, Coupé VMH, et al. Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. Eur J Surg Oncol. 2019;45(5):825-31. DOI: 10.1016/j.ejso.2019.01.225. PMID: 30765270.

Bartlett EK, Lee AY, Spanheimer PM, et al. Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma. Br J Surg. 2020;107(11):1480-8. DOI: 10.1002/bjs.11621. PMID: 32484242.

Namin AW, Cornell GE, Thombs LA, Zitsch RP. Patterns of recurrence and retreatment outcomes among clinical stage I and II head and neck melanoma patients. Head Neck. 2019;41(5):1304-11. DOI: 10.1002/hed.25562. PMID: 30629324.

Ertekin SS, Podlipnik S, Riquelme-Mc Loughlin C, et al. Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence. Acta Derm Venereol. 2021;101(7):adv00502. DOI: 10.2340/00015555-3832. PMID: 34003298.

Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg. 1993;91(1):94-8. DOI: 10.1097/00006534-199301000-00014. PMID: 8416544.

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. Br J Cancer. febrero de 2021;124(3):574-80.

Wan G, Nguyen N, Liu F, DeSimone MS, Leung BW, Rajeh A, Collier MR, Choi MS, Amadife M, Tang K, Zhang S, Phillipps JS, Jairath R, Alexander NA, et al. Prediction of early-stage melanoma recurrence using clinical and histopathologic features. NPJ Precis Oncol. 2022 Oct 31;6(1):79. doi: 10.1038/s41698-022-00321-4.

Coit DG, Ariyan CE. Fifty years of progress in surgical oncology: Melanoma. J Surg Oncol. 2022;126(5):888-95. DOI: 10.1002/jso.27081. PMID: 36087090

Lao CD, Khushalani NI, Angeles C, Petrella TM. Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better? Am Soc Clin Oncol Educ Book. 2022;42:1-7. DOI: 10.1200/EDBK_351153. PMID: 35658502.

Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465-77. DOI: 10.1016/S1470-2045(20)30494-0. PMID: 32961119.

Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-92. DOI: 10.3322/caac.21409. PMID: 29028110.

Park TS, Phan GQ, Yang JC, et al. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Ann Surg Oncol. 2017;24(4):947-51. doi: 10.1245/s10434-017-5768-8. PMID: 28144760.

Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-30. DOI: 10.1016/S1470-2045(15)70122-1. PMID: 25840693.

Thomas DC, Han G, Leong SP, et al. Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. Ann Surg Oncol. 2019;26(7):2254-62. DOI: 10.1245/s10434-019-07369-w. PMID: 31011906.

Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer. 2022;170:236-255. DOI: 10.1016/j.ejca.2022.03.008. PMID: 35570085.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Melanoma: cutaneous. Updated March 2023. Accessed September 22, 2023. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf

Rueth NM, Cromwell KD, Cormier JN. Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am. 2015;24(2):359-77. DOI: 10.1016/j.soc.2014.12.012. PMID: 25769718.

Downloads

Published

2023-10-31

Issue

Section

Review

How to Cite

1.
Patterns of Recurrence of Cutaneous Melanoma: A Literature Review. Dermatol Pract Concept [Internet]. 2023 Oct. 31 [cited 2024 Jul. 13];13(4):e2023304. Available from: https://dpcj.org/index.php/dpc/article/view/3474

Share